In this issue of The Annals, Hodges and White 1 publish an analysis of the world's literature on the value of using some form of cycling of antimicrobial agents to control the emergence of resistance. We congratulate Hodges and White for a job well done. We would like to raise some issues about the definitions of cycling that were used and to point out what we see as some difficulties in their methodology used in the review.
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Antimicrobial cycling is a practice that is implemented in an attempt to prevent the emergence of resistance. The term "antimicrobial cycling" should not be used when referring to a practice that is implemented to try and reverse an already increasing rise in an institution's resistance rates. The authors' interpretation of cycling, and the examples they choose to represent such practice, would more accurately be described as altering antimicrobial prescribing to reduce institutional resistance rates.
The majority of the studies reviewed did not investigate whether antibiotic cycling could prevent resistance. Most of the studies cited were performed because of a preexisting resistance problem in a hospital or nursing unit, with cycling or switching initiated to try and reduce the impact of that resistance. 2-5 For example, in virtually all of the cases, aminoglycoside switching was done because of high levels of gentamicin resistance and the knowledge that amikacin is a semisynthetic aminoglycoside whose struc-ture is not altered by many of the common aminoglycoside-inactivating plasmid-mediated enzymes. 2-3,6-9 In the cases described by Young et al. 2 and Gerding and Larson, 3 a significant decrease was noted in the rates of gentamicin resistance on the initial replacement of gentamicin with amikacin, followed by a subsequent increase in rates once the agent was reintroduced. These trials provide important information regarding the actions and clinical consequences of aminoglycoside-inactivating, plasmid-mediated enzymes when gentamicin is removed and is then reintroduced; however, these studies do not tell us what would result if cycling were to take place before the presence of plasmidmediated enzymes, which is the true purpose of antimicrobial cycling.
In a similar fashion, many of the other trials cited, including the study by Bradley et al., 10 were performed because the institution had high rates of either vancomycin-resistant Enterococcus (VRE) 10 or extended-spectrum β-lactamase-producing Klebsiella pneumoniae (ESBLKP). [11] [12] [13] [14] In virtually all of these cases, third-generation cephalosporins (ceftazidime, in particular), were thought to be responsible for the resistant bacteria through its strong enzyme induction properties. This concept was substantiated by the decreased resistance rates, which closely mirrored the decreased use of third-generation cephalosporins. With the above in mind, we would like to propose two paradigms relating to cycling or switching of antimicrobial agents.
True Antimicrobial Rotation
True antimicrobial rotation would be studied as a measure to prevent resistance to the agents being rotated and to prevent nosocomial infections caused by multidrug-resistant bacteria. For example, a hospital would decide to rotate the use of four different agents in their intensive care units (ICUs) on a quarterly or semiannual basis (the proper time frame is unknown). In these units, for nosocomial infections of all types, the primary empiric antimicrobial agent for nosocomial infections would be piperacillin/ tazobactam, cefepime, meropenem, or levofloxacin. Each of these agents would be used for four or six months at a time, with some rotation planned by random selection. Data on susceptibility of nosocomial pathogens and antimicrobial resistance to each of the agents would be collected for each time period. This would be continued for at least a two-year period of time. The physician would have the option to add a second drug, if it was judged to be necessary, for coverage of bacteria that produce chromosomal type I β-lactamases (e.g., Pseudomonas aeruginosa, Enterobacter cloacae). There are several different strategies and antimicrobial agents that could be used for the purposes of antimicrobial cycling. We have given merely one example in which we used the ICU setting as the target for antimicrobial cycling; however, other units within the institution, such as bone marrow and solid organ transplant units, are certainly potential targets for antimicrobial cycling as well. In all cases, practitioners must keep in mind that antimicrobial cycling is meant to be a preventive measure rather than a treatment measure.
Antibiotic Restriction
Hodges and White provide many examples of antibiotic restriction because of an existing resistance problem. For example, decreasing the use of third-generation cephalosporins, in particular the oxyamino cephalosporins, and the use of alternative agents such as ampicillin/sulbactam or piperacillin/tazobactam, has been shown to reduce the incidence of both VRE and ESBLKP. 10, 13 For outbreaks of imipenem-or meropenem-resistant Acinetobacter spp. or P. aeruginosa, one would restrict the use of the carbapenem to only those situations in which the bacteria are not susceptible to other agents. Data would then be collected to see if the specific resistance issue is corrected.
Summary
Considerable research has been done to assess outcomes following antimicrobial restrictions implemented in attempts to curb existing and growing resistance problems in various institutions throughout the US as evidenced by Hodges and White. At the present time, however, there is not enough information regarding true antimicrobial rotation to determine the efficacy of such practice in minimizing the development of antimicrobial resistance. In our opinion, using the above definitions would help all inter-ested parties to better design and collect data for future studies; however, such practice should not be undertaken as the primary method to prevent resistance outside the realm of research at this time.
